FDA warned Red's Kitchen Sink that claims for Pressure Be Gone and other supplements made them unapproved new drugs.
What happened
FDA reviewed the company's website in January and February 2021 and its Facebook and YouTube pages, which direct consumers to the website to order products. FDA found claims that Pressure Be Gone, Cell Defense Shield, Bony-Barony Detox Tea, and Cell Fuel 102 capsules, powder, and gel are intended to cure, mitigate, treat, or prevent disease. FDA said these products are unapproved new drugs and are misbranded because they lack adequate directions for use.
What FDA found
Website and social media claims show the products are intended to cure, mitigate, treat, or prevent disease, so they are drugs.
section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 321(g)(1)(B)]The products are new drugs because they are not generally recognized as safe and effective for those uses.
section 201(p) of the Act [21 U.S.C. 321(p)]The products are not FDA-approved, and new drugs cannot be sold without approval.
sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d) and 355(a)]The products are misbranded because they lack adequate directions for a layperson to use them safely for their intended uses.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Selling these misbranded drugs in interstate commerce violates the Act.
section 301(a) of the Act [21 U.S.C. 331(a)]The company displays the FDA logo on Cell Fuel 102 capsules and powder, which FDA says is not for private-sector use and may violate federal law.
What FDA wants
FDA asks the company to respond in writing within 15 working days of receiving the letter with the specific steps taken to correct the violations, how it will prevent recurrence, and related documentation. If it cannot complete corrections in that time, it must explain the delay and when it will finish.
Who should pay attention
- online sellers of herbal supplements
- companies making health claims on websites and social media
- brands that use the FDA logo on private-sector products
This is a summary. Read the original letter on fda.gov.